Technical Analysis for PLRX - Pliant Therapeutics, Inc.

Grade Last Price % Change Price Change
F 26.5 1.61% 0.42
PLRX closed up 1.61 percent on Friday, January 22, 2021, on 63 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical PLRX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
50 DMA Resistance Bearish 1.61%
Crossed Above 20 DMA Bullish 1.61%
Fell Below 20 DMA Bearish 4.13%
MACD Bearish Centerline Cross Bearish 4.13%
MACD Bearish Signal Line Cross Bearish 4.13%
50 DMA Resistance Bearish 0.84%
20 DMA Support Bullish 0.84%
Older End-of-Day Signals for PLRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Resistance about 17 hours ago
10 DMA Resistance about 17 hours ago
Up 2% about 17 hours ago
Up 1% about 19 hours ago
20 DMA Support about 20 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pliant Therapeutics, Inc. Description

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Alcohol Steatohepatitis Hepatitis Hepatology Non Alcoholic Fatty Liver Disease Fibrosis Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Drug Design Orphan Drug Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Fibrosis Liver Fibrosis Muscular Dystrophies Primary Sclerosing Cholangitis Integrin

Is PLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 35.63
52 Week Low 19.425
Average Volume 77,503
200-Day Moving Average 0.00
50-Day Moving Average 26.83
20-Day Moving Average 25.91
10-Day Moving Average 26.66
Average True Range 1.64
ADX 13.78
+DI 17.30
-DI 21.43
Chandelier Exit (Long, 3 ATRs ) 23.31
Chandelier Exit (Short, 3 ATRs ) 27.44
Upper Bollinger Band 28.69
Lower Bollinger Band 23.14
Percent B (%b) 0.61
BandWidth 21.43
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0004
Fundamentals Value
Market Cap 940.22 Million
Num Shares 35.5 Million
EPS 0.27
Price-to-Earnings (P/E) Ratio 97.28
Price-to-Sales 10.62
Price-to-Book 3.34
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.29
Resistance 3 (R3) 28.19 27.50 27.99
Resistance 2 (R2) 27.50 27.04 27.55 27.89
Resistance 1 (R1) 27.00 26.76 27.25 27.10 27.79
Pivot Point 26.30 26.30 26.43 26.35 26.30
Support 1 (S1) 25.80 25.85 26.05 25.90 25.21
Support 2 (S2) 25.11 25.56 25.16 25.11
Support 3 (S3) 24.61 25.11 25.01
Support 4 (S4) 24.71